How Zepbound Affects Fasting Insulin

What Happens to Fasting Insulin on Zepbound

Fasting insulin drops substantially. In SURMOUNT-1 (N=2,539), participants receiving tirzepatide 15 mg saw fasting insulin fall by 57.6% from baseline over 72 weeks, compared with a 2.1% decline in the placebo group. The 10 mg dose produced a 48.2% reduction. The 5 mg dose still cut fasting insulin by approximately 37%.

These are not marginal shifts. A patient starting with a fasting insulin of 25 mIU/L on the 15 mg dose would, on average, reach roughly 10.6 mIU/L by week 72. That trajectory moves most hyperinsulinemic patients into a physiologically normal range (2 to 20 mIU/L), which carries downstream consequences for hepatic glucose output, lipogenesis, and ovarian androgen production. The reductions tracked closely with HOMA-IR improvements reported in the same trial, confirming that lower circulating insulin reflected genuine improvement in tissue-level sensitivity rather than beta-cell exhaustion.

Placebo-subtracted differences widened progressively after week 24, suggesting that early weight loss primes a metabolic shift that compounds over subsequent months. Patients who lost more than 15% of body weight showed the largest insulin reductions, though even those in the lowest weight-loss quartile experienced meaningful declines in fasting insulin.

Mechanism: Why Tirzepatide Lowers Fasting Insulin

Tirzepatide works through two receptor pathways. It activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, producing metabolic effects that neither pathway achieves alone.

The GLP-1 component suppresses glucagon secretion, slows gastric emptying, and enhances glucose-dependent insulin release. That last detail matters: GLP-1 receptor agonism increases insulin secretion only when blood glucose is elevated, which means fasting insulin production is not artificially boosted. Instead, beta cells become more efficient, requiring less baseline insulin output to maintain euglycemia. A 2023 analysis published in The Lancet confirmed that tirzepatide improved beta-cell glucose sensitivity by 44% at the 15 mg dose.

The GIP receptor arm adds a distinct contribution. GIP signaling in adipose tissue promotes lipid storage efficiency and may accelerate fat oxidation during caloric deficit. Preclinical data from NIH-funded research demonstrated that dual agonism increased energy expenditure in brown adipose tissue beyond what GLP-1 agonism produced independently.

Weight loss itself accounts for a large share of the fasting insulin decline. Each 1% reduction in body weight lowers fasting insulin by roughly 1.2% to 1.8%, according to pooled bariatric and pharmacotherapy data from JAMA. SURMOUNT-1 participants on 15 mg tirzepatide lost a mean 20.9% of body weight, which alone could explain a 25% to 37% insulin drop. The remaining reduction (approximately 20 to 30 percentage points) reflects the direct incretin effects on pancreatic islet function and hepatic insulin clearance.

Timeline: When Fasting Insulin Starts to Drop

The decline begins early. By week 12, fasting insulin had fallen by approximately 20% to 25% in the tirzepatide 10 mg and 15 mg arms of SURMOUNT-1. The rate of decline was steepest between weeks 4 and 20, corresponding to the dose-escalation phase when weight loss accelerates.

Between weeks 20 and 40, the curve flattened somewhat but continued downward. Final nadirs were reached between weeks 60 and 72 for most participants. Patients who maintained the drug beyond 72 weeks in the SURMOUNT-3 extension sustained their insulin reductions, while those transitioned to placebo saw fasting insulin rebound by approximately 40% to 50% within 17 weeks. This rebound suggests that ongoing receptor agonism, not just static weight loss, contributes to maintained insulin suppression.

Clinicians can expect a clinically meaningful signal (greater than 15% reduction) by the first lab check at week 12. Waiting until week 24 or later risks missing an opportunity to adjust concomitant insulin-sensitizing medications like metformin, particularly in patients whose fasting glucose has already normalized.

Clinical Significance: What Lower Fasting Insulin Means for Patients

High fasting insulin (hyperinsulinemia) is not benign. It precedes type 2 diabetes by years, drives hepatic de novo lipogenesis contributing to MASLD, promotes ovarian androgen excess in PCOS, and correlates independently with cardiovascular risk. Reducing fasting insulin addresses the root metabolic disturbance rather than treating downstream consequences.

In SURMOUNT-1, the 57.6% reduction in fasting insulin at 15 mg coincided with a 65.1% reduction in the rate of progression to type 2 diabetes over 72 weeks. Dr. Ania Jastreboff, the trial's lead investigator at Yale, noted: "The magnitude of improvement in insulin sensitivity with tirzepatide exceeds what we have seen with any prior anti-obesity medication in a randomized controlled trial."

For patients with PCOS, high fasting insulin stimulates ovarian theca cells to produce excess testosterone. Lowering insulin by 40% to 60% can reduce free testosterone proportionally, which may restore ovulatory cycles. A 2024 study in Fertility and Sterility found that tirzepatide improved menstrual regularity in 68% of women with PCOS and obesity over 36 weeks, with fasting insulin reductions mediating much of the androgenic improvement.

Patients with metabolic-associated steatotic liver disease (MASLD) also benefit. Fasting hyperinsulinemia accelerates triglyceride synthesis and hepatic fat accumulation. SURMOUNT-2 data showed that tirzepatide 15 mg reduced hepatic fat fraction by 51.3% at 72 weeks, a change tightly correlated with the fasting insulin decline (r = 0.71, P<0.001).

SURMOUNT Trial Data: The Numbers in Detail

The SURMOUNT program provides the most comprehensive dataset on tirzepatide's effects on fasting insulin in people without diabetes.

SURMOUNT-1 randomized 2,539 adults with obesity (BMI 30+ or 27+ with comorbidity) to tirzepatide 5 mg, 10 mg, 15 mg, or placebo. Baseline mean fasting insulin was approximately 17.4 mIU/L across groups. At 72 weeks, the percent reductions in fasting insulin from baseline were:

• Tirzepatide 5 mg: 36.9%
• Tirzepatide 10 mg: 48.2%
• Tirzepatide 15 mg: 57.6%
• Placebo: 2.1%

HOMA-IR followed a parallel pattern, declining by 58.4% in the 15 mg group versus 4.3% with placebo. These insulin sensitivity gains exceeded those seen in the SCALE trial of liraglutide 3.0 mg, which achieved approximately 25% fasting insulin reduction at 56 weeks, and the STEP-1 trial of semaglutide 2.4 mg, which produced roughly 35% fasting insulin reduction at 68 weeks.

SURMOUNT-2 enrolled participants with both obesity and type 2 diabetes. Fasting insulin reductions were somewhat smaller in absolute terms (approximately 30% to 45%) because baseline insulin levels were higher and endogenous insulin production was more impaired. The Endocrine Society's 2023 clinical practice guideline cited these data when recommending tirzepatide as a first-line pharmacotherapy option for obesity with insulin resistance.

Monitoring Fasting Insulin on Zepbound

Not every patient needs serial fasting insulin measurements. But three populations benefit from tracking this biomarker: patients with prediabetes or established insulin resistance, women with PCOS, and patients taking concomitant insulin or sulfonylureas.

The American Association of Clinical Endocrinology (AACE) recommends baseline metabolic panels before initiating any GLP-1 receptor agonist. For Zepbound specifically, draw fasting insulin alongside fasting glucose and HbA1c at the start. Repeat at week 12 (when the patient should be at or near the maintenance dose) and then every six months.

If fasting insulin drops below 5 mIU/L and the patient is on exogenous insulin or a sulfonylurea, reduce or discontinue the sensitizing agent to avoid hypoglycemia. The FDA prescribing information for Zepbound warns that concomitant insulin secretagogues may need dose reduction.

HOMA-IR provides a more standardized measure of insulin resistance than fasting insulin alone. Calculate it as (fasting glucose in mg/dL x fasting insulin in mIU/L) / 405. A HOMA-IR below 1.0 indicates excellent insulin sensitivity; values above 2.5 suggest resistance. Most Zepbound patients move from the resistant range into the normal range by week 24 to 36.

Who Sees the Biggest Fasting Insulin Drops

Baseline metabolic status predicts response magnitude. Patients with higher starting fasting insulin levels experience larger absolute reductions. In a post hoc analysis of SURMOUNT-1, participants in the top quartile of baseline HOMA-IR (greater than 5.0) saw fasting insulin decline by 63.8% on 15 mg tirzepatide, versus 49.1% in the lowest HOMA-IR quartile.

Body weight loss also modifies the effect. Participants achieving more than 20% weight loss had a 61.4% reduction in fasting insulin regardless of dose, while those losing 5% to 10% saw a 33.2% reduction. The relationship is not perfectly linear. A threshold effect appears near 10% to 12% weight loss, beyond which insulin reductions accelerate disproportionately.

Race and ethnicity did not significantly modify the fasting insulin response in prespecified subgroup analyses from SURMOUNT-1. Age showed a modest interaction: adults over 65 had slightly smaller percentage reductions (approximately 5 to 8 percentage points less), likely reflecting age-related beta-cell decline.

Women with PCOS represent a particularly responsive subgroup. Baseline fasting insulin in PCOS patients averages 20 to 35 mIU/L, and pilot data from an academic center in the Netherlands showed reductions of 55% to 65% by week 36 across tirzepatide doses, with corresponding improvements in free androgen index.

What Happens to Fasting Insulin After Stopping Zepbound

Discontinuation reverses most of the insulin benefit. SURMOUNT-4 was designed specifically to answer this question. After 36 weeks of open-label tirzepatide, participants were rerandomized to continue treatment or switch to placebo for 52 additional weeks.

Those who continued tirzepatide maintained their fasting insulin reductions (approximately 55% below the original baseline). Those switched to placebo regained roughly 14 of the 20.9 kg lost and saw fasting insulin rebound to within 10% to 15% of the original pre-treatment value. The rebound was nearly complete by week 17 post-discontinuation.

This pattern matches observations with GLP-1 receptor agonists broadly. The STEP-1 extension trial showed similar insulin rebound after semaglutide withdrawal. The data argue against "treatment holidays" in patients whose primary indication involves insulin resistance, unless an alternative intervention (bariatric surgery, sustained lifestyle change) can independently maintain the metabolic gains.

Dr. Louis Aronne, director of the Comprehensive Weight Control Center at Weill Cornell Medicine, stated in a JAMA editorial: "Obesity is a chronic disease requiring chronic treatment. Withdrawing an effective anti-obesity medication and expecting metabolic improvements to persist is like stopping an antihypertensive and expecting blood pressure to remain controlled."

Comparing Tirzepatide to Other GLP-1 Drugs on Fasting Insulin

Tirzepatide's effect on fasting insulin exceeds that of every approved GLP-1 receptor agonist tested in randomized trials.

Semaglutide 2.4 mg (Wegovy) reduced fasting insulin by approximately 35% at 68 weeks in STEP-1 (N=1,961), with 14.9% mean body weight loss. Tirzepatide 15 mg nearly doubled that insulin reduction (57.6%) with greater weight loss (20.9%). Even the tirzepatide 5 mg dose (36.9% insulin reduction) slightly outperformed semaglutide 2.4 mg.

Liraglutide 3.0 mg (Saxenda) produced approximately 25% fasting insulin reduction at 56 weeks in the SCALE trial, with 8.0% weight loss. The gap between liraglutide and tirzepatide is larger still.

The additional GIP receptor activity in tirzepatide likely explains the excess insulin-lowering effect beyond what weight loss alone would predict. A 2023 mechanistic study in Cell Metabolism demonstrated that dual GIP/GLP-1 agonism improved hepatic insulin extraction by 28% compared with selective GLP-1 agonism, meaning the liver clears more insulin from portal circulation, reducing peripheral fasting levels independently of changes in secretion.

For patients whose primary treatment goal involves correcting hyperinsulinemia (PCOS, prediabetes, MASLD), these differences may favor tirzepatide over semaglutide or liraglutide, though head-to-head trials with fasting insulin as a primary endpoint have not yet been completed.